British Journal of Haematology, EarlyView.Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas +35 more
wiley +1 more source
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
Advances in Hematology, 2012 JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms.
Mar Bellido, Peter A. W. te Boekhorst
doaj +1 more source
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
Revista Brasileira de Hematologia e Hemoterapia, 2015 Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative ...
Renata Mendes de Freitas +1 more
doaj +1 more source
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia [PDF]
, 2011 BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Cerutti, Janete Maria +5 more
core +3 more sources
Cancer Science, EarlyView.Whole‐genome sequencing of ~50,000 individuals from the Tohoku Medical Megabank (TMM) cohort defines the prevalence, mutational landscape, and age dependency of clonal hematopoiesis in the Japanese population, demonstrating overall concordance with clonal hematopoiesis detected in cancer patients.
SungGi Chi +12 more
wiley +1 more source
Progress against non-Hodgkin lymphoma in the Netherlands: Incidence, patterns of care and prognosis since 1989 (Studies with cancer registry data) [PDF]
, 2010 Cancers arising from the haematopoietic and lymphoid tissue comprise a heterogeneous group of malignancies with diverse clinical and biological features.
Schans, S.A.M. (Saskia) van de
core
Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms [PDF]
, 2010 We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally.
Cheung, AMS +4 more
core +1 more source
A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen +5 more
wiley +1 more source
Mutation and Lineage Analysis of DNMT3A in BCR-ABL1-negative Chronic Myeloproliferative Neoplasms
International Journal of Gerontology, 2013 In addition to the JAK2 V617F mutation, somatic mutation in DNMT3A has been described in BCL-ABL1-negative myeloproliferative neoplasms (MPNs).
Huan-Chau Lin +13 more
doaj +1 more source